Indian Drugs and Pharmaceuticals Limited

From WikiMD.com Medical Encyclopedia

State-owned pharmaceutical company in India



Indian Drugs and Pharmaceuticals Limited (IDPL) is a public sector undertaking in India that was established to achieve self-sufficiency in the field of pharmaceuticals. It was founded in 1961 and is headquartered in New Delhi.

History[edit | edit source]

IDPL Hyderabad facility

The establishment of IDPL was a significant step in the Indian government's efforts to promote the domestic production of pharmaceuticals and reduce dependency on imports. The company was set up with the assistance of the Soviet Union, which provided technical and financial support. The primary objective was to manufacture essential drugs and make them available at affordable prices to the Indian population.

IDPL played a crucial role in the development of the pharmaceutical industry in India. It was instrumental in the production of bulk drugs and formulations, which laid the foundation for the growth of the private pharmaceutical sector in the country.

Operations[edit | edit source]

IDPL operates several manufacturing facilities across India, including major plants in Hyderabad, Rishikesh, and Gurgaon. These facilities are involved in the production of a wide range of pharmaceutical products, including antibiotics, analgesics, and anti-inflammatory drugs.

The company has faced several challenges over the years, including financial difficulties and competition from the private sector. Despite these challenges, IDPL continues to be a key player in the Indian pharmaceutical industry, contributing to the availability of affordable medicines.

Products[edit | edit source]

IDPL manufactures a variety of pharmaceutical products, including:

  • Antibiotics
  • Analgesics
  • Anti-inflammatory drugs
  • Vitamins and nutritional supplements

The company focuses on producing generic drugs to ensure that essential medicines are accessible to the general population at reasonable prices.

Challenges and Future Prospects[edit | edit source]

IDPL has faced numerous challenges, including financial constraints and the need for modernization of its facilities. The company has been under financial stress due to accumulated losses and has been exploring various options for revival, including strategic partnerships and government support.

The future prospects of IDPL depend on its ability to modernize its operations, improve efficiency, and compete with private sector companies. The Indian government has been considering various measures to revitalize IDPL, recognizing its importance in ensuring drug security in the country.

Related pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD